Forensic data analytics
Globally integrated compliance review, litigation support and investigative services
EY forensic data analytics

Data is everywhere. From complex general ledger accounting systems to network security and social media, it is the all-encompassing backbone of corporate America. If you are responding to litigation issues or regulatory demands, are engaged in an investigation or are trying to prevent one, you will need to understand complex data sets from multiple sources within your business. The key to making sense of and commanding this rapidly expanding frontier is to effectively leverage new technology in conjunction with subject matter professionals who are focused on the relevance to your industry.

EY’s forensic data analytics (FDA) combines the extensive use of big data and statistical and qualitative analysis, in conjunction with explanatory and predictive models, to guide and identify issues and areas warranting further review. Our fact-based evidence drives actionable business decisions, focuses investigative efforts where it matters and optimizes outcomes. Our suite of FDA service offerings comprises proactive and reactive methodologies that leverage the information contained in large-scale, structured and unstructured client data sets. This allows us to more efficiently detect and investigate instances of error, waste, misuse, abuse, corruption, noncompliance and fraud, or to assist in a regulatory or litigation response. With the integration of third-party data into our suite of FDA tools, our professionals are able to effectively exploit internal data with relevant external or third-party intelligence such as country sanctions lists, legal proceedings or adverse media checks. EY’s FDA platform avoids unnecessary client costs by transforming large disparate data sets into actionable analyses and patterns that assist in answering the critical questions at issue.

Forensic data analytics solutions

Fraud Risk and Compliance
- Fraud detection and risk management
- Regulatory proceedings
- Bribery and corruption
- Financial statement fraud
- Asset misappropriation
- Competition law
- Quantum loss estimation
- Transaction due diligence
- Financial crime
- Corporate restructuring
- Third-party due diligence

Customizable business process
- Contract management
- Electronic payment systems
- Sales and marketing
- E-commerce
- Procure-to-pay
- Insurance claims
- Time and expense
- Human resources
- Enterprise resource planning
- Customer relationship management

Advanced Data Analytics
- Multi data acquisition
- Automated data mapping
- Investigative data linking
- Social network analysis
- Data visualization
- Statistical inference
- Text mining and analysis
- Artificial intelligence
- Predictive modelling
- Unsupervised pattern recognition
- Programming and decision support

Data is everywhere. From complex general ledger accounting systems to network security and social media, it is the all-encompassing backbone of corporate America. If you are responding to litigation issues or regulatory demands, are engaged in an investigation or are trying to prevent one, you will need to understand complex data sets from multiple sources within your business. The key to making sense of and commanding this rapidly expanding frontier is to effectively leverage new technology in conjunction with subject matter professionals who are focused on the relevance to your industry.

EY’s forensic data analytics (FDA) combines the extensive use of big data and statistical and qualitative analysis, in conjunction with explanatory and predictive models, to guide and identify issues and areas warranting further review. Our fact-based evidence drives actionable business decisions, focuses investigative efforts where it matters and optimizes outcomes. Our suite of FDA service offerings comprises proactive and reactive methodologies that leverage the information contained in large-scale, structured and unstructured client data sets. This allows us to more efficiently detect and investigate instances of error, waste, misuse, abuse, corruption, noncompliance and fraud, or to assist in a regulatory or litigation response. With the integration of third-party data into our suite of FDA tools, our professionals are able to effectively exploit internal data with relevant external or third-party intelligence such as country sanctions lists, legal proceedings or adverse media checks. EY’s FDA platform avoids unnecessary client costs by transforming large disparate data sets into actionable analyses and patterns that assist in answering the critical questions at issue.

Forensic data analytics solutions

Fraud Risk and Compliance
- Fraud detection and risk management
- Regulatory proceedings
- Bribery and corruption
- Financial statement fraud
- Asset misappropriation
- Competition law
- Quantum loss estimation
- Transaction due diligence
- Financial crime
- Corporate restructuring
- Third-party due diligence

Customizable business process
- Contract management
- Electronic payment systems
- Sales and marketing
- E-commerce
- Procure-to-pay
- Insurance claims
- Time and expense
- Human resources
- Enterprise resource planning
- Customer relationship management

Advanced Data Analytics
- Multi data acquisition
- Automated data mapping
- Investigative data linking
- Social network analysis
- Data visualization
- Statistical inference
- Text mining and analysis
- Artificial intelligence
- Predictive modelling
- Unsupervised pattern recognition
- Programming and decision support
EY is positioned to meet the complex and evolving demands of the current business landscape by leveraging our people, processes and technology. Our service offerings are managed and performed by industry professionals, globally integrated for standardized methodologies and practices, and executed with advanced technology.

Our FDA service offerings are integrated across international borders. Our FDA teams around the world bring together their local experience to handle simultaneous multinational assignments on tight deadlines. These professionals are familiar with local data transfer and privacy rules, state secrecy laws and other local requirements affecting international forensic data analytics. Each of our FDA professionals, regardless of location, is trained to adhere to our internal procedures for handling structured and unstructured data and to leverage our common technology platform.

Our common global technology platform further supports this integration. We coordinate research and development in forensic labs positioned in strategic locations around the globe to provide an FDA platform to manage multiple challenges: small, large, common or unique. For large matters, our data centers are standardized on several advanced hosting and review platforms. In cases where our technology must be complemented to meet your specific needs, our teams remain flexible to adapt to your IT solution set. Additionally, our team can deploy our full suite of FDA products in a fully secure mobile environment that sits within your data infrastructure protected by your data security protocols.

**EY’s global FDA footprint**

![Global Footprint Graphic]
Investigations and dispute services

EY offers customizable, industry-specific analytics solutions that leverage various forms of data such as accounting, supply chain data, marketing, logistics, social media, internet/intranet, business intelligence and audio/Voice over Internet Protocol (VoIP). These solutions are designed to assist our clients in answering the unique challenges to their industry.

Decision support

Complex business decisions require complex decision support analysis. EY’s decision support management tools are an internally developed, web-based, interactive environment that manages client data from receipt through archival, allows multiple users real-time access to the data and documents, and provides a fast and easy mechanism for complying with regulatory requests and investigation or litigation demands. The tool is further supported by independent verification and validation tests through the tools reporting and analytics function to enhance consistency in the decision-making process.

Anti-bribery and corruption (ABaC) analytics

EY has collaborated with the Association of Certified Fraud Examiners and leading global organizations to develop a library of innovative anti-fraud/anti-corruption analytics to choose from that are customizable on a case-by-case, country-by-country basis. The key differentiator that makes ABaC analytics a preferred choice is the risk-based approach that quickly identifies target areas for internal audit and compliance testing, integrating structured and unstructured data elements targeted to identify potentially improper payments.

Anti-fraud and rogue employee analytics

Integrating statistics, accounting, text mining and big data techniques, anti-fraud analytics are designed to identify rogue employee risks in a variety of business contexts. In the financial services industry, our suite of anti-fraud and rogue employee analytics combine the experience of financial service and forensic professionals to identify rogue trader risks by analyzing communication patterns and emotive tone in email and instant message communications as well as transactional data to identify patterns of suspicious activity. In the life science industry, our field force monitoring suite of analytics combines relevant industry experience with forensic professionals to develop algorithms that seek to identify patterns of off label marketing, speaker program abuse and other rogue employee activities from both email, call notes, travel and entertainment, and event data. Similar algorithms exist for other industries, including oil and gas and aerospace and defense, and can be deployed locally or via a secure web-based platform. Leveraging advanced data mining and big data tool sets, our library of hundreds of anti-fraud tests can be tailored to meet your specific fraud risk areas to identify rogue employee activity on an objective, repeatable basis.

Anti-money laundering and compliance

The combination of anti-fraud and anti-money laundering (FRAML) is a recently developed model that aims to increase the parity and transparency of data sources and information through the consolidation of fraud and anti-money laundering (AML) resources. FRAML attests that in addition to the compliance procedures, AML investigations must include a team of knowledgeable professionals from the compliance, legal and fraud departments, who not only have experience within their respective fields but also have the capability to adapt their investigative techniques to the AML environment.

Third-party due diligence

The economic crisis, recent governmental enforcements and the increased focus on enterprise risk are causing global corporations and their audit committees to take a closer look at how they manage their vendor and customer compliance relations. EY has assisted many companies in dealing with these issues and has industry experience in building compliance programs that address known vendor corruption risk.
Global industry sectors

- Asset management
- Banking and capital markets
- Consumer products
- Insurance
- Media and entertainment
- Oil and gas
- Private equity
- Technology
- Automotive
- Cleantech
- Government and public
- Life sciences
- Mining and metals
- Power and utilities
- Real estate
- Telecommunications
Our FDA process

Today, an hour’s worth of business for a typical Fortune 1000 company can create millions of transactional records. The entirety of data from the private sector doubles every 14 months. Big data is no longer a phenomenon but a vastly expanding data footprint in our everyday course of business. This data footprint is at the core of most regulatory matters, investigations and complex business issues.

Our FDA professionals, including certified public accountants, certified fraud examiners, business and computer science professionals, and industry subject-matter professionals, employ advanced analytics, relationship forensics, linguistics analysis and data visualizations tools. These tools allow the data to define itself and can automatically detect inconsistencies within large amounts of transactional data. Complementing their depth of experience in sophisticated multinational investigations and cases, they include internationally recognized thought leaders in forensic data analytics who have led many high-profile matters involving a wide range of compliance, regulatory and litigation proceedings.

EY FDA process

Our process begins with a thorough understanding of your business, industry and specific challenges associated with forensic data analytics. We deploy model-based analytics that help answer the following questions:

- Who is talking to whom?
- What are they talking about?
- Who is involved?
- When did it start?
- Over what time period has it taken?
- What is the magnitude?
- What are the outliers?
- Is my risk/compliance approach effective?
- Are there unidentified areas of risk within my organization?
- What was the root cause?

Relationship and entity link analysis
Beyond traditional “rules-based” queries and analytics

FDA method maturities

Our approach to forensic data analysis incorporates targeted model-based mining and visual analytics tools that allow the data to “speak for itself.” When deployed over large data sets, our analytics can be a powerful tool to identify large and unusual transactions or anomalies derived from the multidimensional attributes within your data. Model-based mining, which leverage our suite of FDA analytics techniques to shift the focus to high-risk areas where controls may not necessarily exist or are perhaps even bypassed. We integrate our visual analytics approach to assist counsel with identifying patterns in the data that can be more clearly defined as demonstrated below.

Representative business application examples

EY's multi-format data conversion platform transforms and integrates disparate data sets regardless of their source systems to support various regulatory matters, litigation support, fraud investigations and disputes, third-party due diligence, anti-bribery and corruption investigations, compliance review, decision support and more.

FDA's artificial intelligence analytics rules-based methodology applies business rules logic and or regulatory or litigation requirements to identify and understand data populations.

Large-scale data link analysis can be leveraged to trace complex financial transactions, visualize entity and relationships, and identify anomalous patterns.

Text mining, sentiment analysis and concept mapping can be used in fraud, corruption, waste and abuse matters in an effort to identify transactions, e-mail, or text based data that has terms or phrases of known concern and or to detect the emotions associated with the data.

EY's FDA approach also combines the extensive use of statistical and qualitative analysis to identify data of interest based on the facts of the investigation, litigation matter or dispute.

Relationship visualizations and transaction analysis can be applied to various investigative and dispute cases helping to provide clarity around how people, data and entities are connected.

<table>
<thead>
<tr>
<th>FDA technique</th>
<th>Representative business application examples</th>
</tr>
</thead>
<tbody>
<tr>
<td>Multiformal data conversion</td>
<td>EY's multi-format data conversion platform transforms and integrates disparate data sets regardless of their source systems to support various regulatory matters, litigation support, fraud investigations and disputes, third-party due diligence, anti-bribery and corruption investigations, compliance review, decision support and more.</td>
</tr>
<tr>
<td>Artificial intelligence analysis</td>
<td>FDA's artificial intelligence analytics rules-based methodology applies business rules logic and or regulatory or litigation requirements to identify and understand data populations.</td>
</tr>
<tr>
<td>Large-scale data link analysis</td>
<td>Large-scale data link analysis can be leveraged to trace complex financial transactions, visualize entity and relationships, and identify anomalous patterns.</td>
</tr>
<tr>
<td>Text mining, sentiment analysis and concept mapping</td>
<td>Text mining, sentiment analysis and concept mapping can be used in fraud, corruption, waste and abuse matters in an effort to identify transactions, e-mail, or text based data that has terms or phrases of known concern and or to detect the emotions associated with the data.</td>
</tr>
<tr>
<td>Statistical inference, representative sampling and hypothesis testing</td>
<td>EY's FDA approach also combines the extensive use of statistical and qualitative analysis to identify data of interest based on the facts of the investigation, litigation matter or dispute.</td>
</tr>
<tr>
<td>Relationship visualization &amp; transaction flow analysis</td>
<td>Relationship visualizations and transaction analysis can be applied to various investigative and dispute cases helping to provide clarity around how people, data and entities are connected.</td>
</tr>
</tbody>
</table>
Our reports convey our results in a visual manner for easy interpretation and anomaly detection so that general counsel, outside legal advisors, internal auditors, risk managers and IT professionals can identify issues and respond to regulatory inquiries, litigation, investigative and compliance issues. Our visual displays also can be used to help improve business performance, reduce unnecessary costs and identify unassuming areas of risk.

**FDA data representation**

EY has a proven track record in conducting large scale database investigations that have uncovered a variety of fraud schemes, including, but not limited to, check fraud, theft, corruption, Foreign Corrupt Practices Act violations, procurement kickback schemes, conflicts of interest and financial misstatement schemes.

**Rapid-fire analysis**

- Graphically represent relationships between seemingly discrete entities.
- Easily identify commonalities between objects – e.g., customers with identical addresses.
- One-click export to Excel.
- Cull data by specifying a date range.
Rogue employee comparison analysis

Accounts payable stratification analysis
On-site mobile data center

Many litigation, investigative and dispute matters require data or other electronically stored information to remain under lock and key on the client’s premises. EY’s FDA professionals can deploy our FDA platform on-site and on a global scale via our mobile data center (MDC). The MDC leverages EY’s FDA mobile computing technology while maintaining the client’s data privacy and security protocols.

Industry-leading technology

• EY’s full suite of FDA software supports custom configurations based on client requirements

Mobility

• Behind your firewall – fiber optic uplink connectivity to client’s network (10GbE)
• Portability – quick deployment of a powerful IT infrastructure to any country
• Closed network – elimination of privacy and security concerns
• Rapid implementation – operational in 60 minutes from site deployment

Scalability

• Processing – highly capable standard configuration with multiple options to enable higher levels of throughput
• Flexible network integration – high-speed network capability with options for access control ranging from tight integration to full air-gap stand-alone environment
• 5TB NAS storage – fast, reliable and redundant
• Stackable units – provides for scalability of up to eight units
• Enterprise-grade hardware – mobile to permanent solution via direct data center environment integration
About EY
EY is a global leader in assurance, tax, transaction and advisory services. The insights and quality services we deliver help build trust and confidence in the capital markets and in economies the world over. We develop outstanding leaders who team to deliver on our promises to all of our stakeholders. In so doing, we play a critical role in building a better working world for our people, for our clients and for our communities.

EY refers to the global organization, and may refer to one or more, of the member firms of Ernst & Young Global Limited, each of which is a separate legal entity. Ernst & Young Global Limited, a UK company limited by guarantee, does not provide services to clients. For more information about our organization, please visit ey.com.

Ernst & Young LLP is a client-serving member firm of Ernst & Young Global Limited operating in the US.

© 2013 Ernst & Young LLP.
All Rights Reserved.

SCORE no. WW0302
BSC no. 1309-1133252
ED None

This publication contains information in summary form and is therefore intended for general guidance only. It is not intended to be a substitute for detailed research or the exercise of professional judgment. Neither Ernst & Young LLP nor any other member of the global Ernst & Young organization can accept any responsibility for loss occasioned to any person acting or refraining from action as a result of any material in this publication. On any specific matter, reference should be made to the appropriate advisor.

ey.com